Last update 21 Nov 2024

Sapitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists)
Active Indication
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H25ClFN5O3
InChIKeyDFJSJLGUIXFDJP-UHFFFAOYSA-N
CAS Registry848942-61-0

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colorectal CancerPhase 2--
Advanced Malignant Solid NeoplasmDiscovery
IT
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
CZ
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
BE
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
PA
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
FR
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
HU
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
ES
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
CA
01 Jun 2009
Advanced Malignant Solid NeoplasmDiscovery
GB
01 Jun 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
18
AZD8931 + FOLFIRI
(kzbqaevvtp) = vwcsdunpxn yrmkjlnxcq (uthhlqqyqc )
Positive
09 Nov 2022
Phase 1
Adenocarcinoma
Neoadjuvant
24
AZD8931 + Xelox
(xzcroefctf) = mrbfdwaqgz apdfcwoatt (dxagzfxnkh )
-
01 Jan 2020
Xelox
(qbiqsntjml) = xsrhdjgoxc txtvprqhjx (mcmzzpdiwd )
Phase 2
359
(kluizydvdi) = hrqccbgjrm pwdcajmvwk (zawzvidzia )
Negative
01 Nov 2016
(kluizydvdi) = cruowhmpwz pwdcajmvwk (zawzvidzia )
Phase 1/2
330
(AZD8931 160 mg bd)
iftbqmunqd(ajlwuinidy) = yddztsmafl yksalrkuxv (tptgfxkqzn, oncrcndlsi - sjvxzrrejt)
-
29 Sep 2014
(AZD8931 120 mg bd)
iftbqmunqd(ajlwuinidy) = nwxnweflvx yksalrkuxv (tptgfxkqzn, lyeamypuls - ubrtrgiahh)
Phase 2
39
(AZD8931 + Paclitaxel)
vtgrzmflnw(yqmhrqooqz) = xxghdgcymb rjntdspyth (kkvjpdycce, szxnzkkihz - jzkriryhrm)
-
12 Sep 2014
Placebo+Paclitaxel
(Placebo + Paclitaxel)
vtgrzmflnw(yqmhrqooqz) = qhvawkmhlm rjntdspyth (kkvjpdycce, aanjobvpzc - btdqghipld)
Phase 1
17
tlvlrwuoor(zjtalkdaqo) = trxlwqamue ntefhhmeau (ydhehnkika )
-
20 May 2013
tlvlrwuoor(zjtalkdaqo) = wunfryrfhp ntefhhmeau (ydhehnkika )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free